Investor Guide – BioMarin Pharmaceutical Executive Summary

By Naomi Wentworth • Tuesday, May 05 16:04 • Permanent Link

Shares of Health Care sector company BioMarin Pharmaceutical moved -4.0% today, and are now trading at a price of $53.24. The Large-Cap stock's daily volume was 3,794,019 compared to its average volume of 2,002,896. The S&P 500 index returned a 1.0% performance.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company is based in San Rafael and has 3,221 full time employees. Its market capitalization is $10,289,696,768.

24 analysts are following BioMarin Pharmaceutical and have set target prices ranging from $55.0 to $120.0 per share. On average, they have given the company a rating of buy. At today's prices, BMRN is trading -40.93% away from its average analyst target price of $90.12 per share.

Over the last year, BMRN shares have gone down by -7.0%, which represents a difference of -35.4% when compared to the S&P 500. The stock's 52 week high is $66.28 per share and its 52 week low is $50.76.

None

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.